Update in HIV Medicine for the Generalist

  • Amina A. Chaudhry
  • Allen L. Gifford
  • Joseph Cofrancesco Jr.
  • James Sosman
  • Gail Berkenblit
  • Lynn E. Sullivan
Update
  • 35 Downloads

References

  1. 1.
    Siegfried N, Muller M, Deeks J, et al. HIV and male circumcision–a systematic review with assessment of the quality of studies. Lancet Infect Dis. 2005;5(3):165–73. Mar.PubMedGoogle Scholar
  2. 2.
    Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 trial. PLoS Med. 2005;211:e298. Nov.PubMedCrossRefGoogle Scholar
  3. 3.
    Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet. 2007;369:643–56.PubMedCrossRefGoogle Scholar
  4. 4.
    Wawer M, Kigozi G, Serwadda D, et al. Trial of male circumcision in HIV+ men, Rakai, Uganda: Effects in HIV+ men and in women partners. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA. February 3–6, 2008. Abstract 33LB.Google Scholar
  5. 5.
    Joint United Nations Programme on HIV/AIDS, World Health Organization. New Data on Male Circumcision and HIV Prevention: Policy and Programme Implications. 2007. Available at: http://data.unaids.org/pub/Report/2007/mc_recommendations_en.pdf. Accessed September 29, 2008.
  6. 6.
    Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR. Centers for Disease Control. 2006;55RR-141–17.Google Scholar
  7. 7.
    Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med. 2005;352:586–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2006 October 10, 2006. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL000629.pdf. Accessed September 29, 2008.
  10. 10.
    Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2007 December 1, 2007. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL000721.pdf. Accessed September 29, 2008.
  11. 11.
    Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–60. Jan 19.PubMedCrossRefGoogle Scholar
  12. 12.
    Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA. February 3–6, 2008. Abstract 790.Google Scholar
  13. 13.
    Johnson M, Campbell T, Clotet B, et al. DUET-2: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA. February 3–6, 2008. Abstract 791.Google Scholar
  14. 14.
    Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466–75.PubMedCrossRefGoogle Scholar
  15. 15.
    Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22:1389–97.PubMedCrossRefGoogle Scholar
  16. 16.
    Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–78.PubMedCrossRefGoogle Scholar
  17. 17.
    Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial. Lancet. 2007;370:49–58.PubMedCrossRefGoogle Scholar
  18. 18.
    Hardy D, Reynes J, Kornourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA. February 3–6, 2008. Abstract 792.Google Scholar
  19. 19.
    Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine/lamivudine), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: Week 48 results of the MERIT study. Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia. July 22–25, 2007. Abstract WESS104.Google Scholar
  20. 20.
    Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–54.PubMedCrossRefGoogle Scholar
  22. 22.
    Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;10:1603–14.CrossRefGoogle Scholar
  23. 23.
    Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed September 29, 2008.
  27. 27.
    Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction: The data collection on adverse events of anti-HIV drugs (DAD) study group. N Engl J Med. 2003;349:1993–2003.PubMedCrossRefGoogle Scholar
  28. 28.
    Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–62.PubMedGoogle Scholar
  29. 29.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. DHHS adults and adolescents antiretroviral treatment guidelines Panel’s communication regarding abacavir. Available at: http://aidsinfo.nih.gov/contentfiles/ABCComm.pdf. Accessed September 29, 2008.

Copyright information

© Society of General Internal Medicine 2008

Authors and Affiliations

  • Amina A. Chaudhry
    • 1
  • Allen L. Gifford
    • 2
  • Joseph Cofrancesco Jr.
    • 1
  • James Sosman
    • 3
  • Gail Berkenblit
    • 1
  • Lynn E. Sullivan
    • 4
  1. 1.Department of MedicineJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of MedicineVA New England Healthcare and Boston University School of MedicineBostonUSA
  3. 3.Department of MedicineUniversity of Wisconsin School of MedicineMadisonUSA
  4. 4.Department of MedicineYale University School of MedicineNew HavenUSA
  5. 5.Division of General Internal MedicineJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations